CompanyGraph
Xuanzhu Biopharmaceutical Co., Ltd.
2575 · HKEX · China
Price data from its V59 listing on FSX, quoted in EUR
xuanzhubio.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $15.42M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
32.63BHKD4.16B · vs all stocks (USD)
Revenue (TTM)
120.99MHKD15.42M · vs all stocks (USD)
Profit Margin
-203.19%52-Week Change
-64.81%vs all stocks
Market Capitalization
32.63BHKD4.16B · vs all stocks (USD)
Enterprise Value
5.02BHKD639.69M · vs all stocks (USD)
Price to Sales (TTM)
46.40xPrice to Book (MRQ)
3.17xEnterprise to Revenue
41.48xEnterprise to EBITDA
-24.71xProfit Margin
-203.19%Operating Margin
-113.58%Return on Assets (TTM)
-9.68%Return on Equity (TTM)
-19.61%Revenue (TTM)
120.99MHKD15.42M · vs all stocks (USD)
Revenue per Share (TTM)
0.2070HKDUpdated Sep 20, 2026Quarterly Revenue Growth
288.10%Gross Profit (TTM)
36.12MHKD4.60M · vs all stocks (USD)
EBITDA (TTM)
-203.05MHKD-25.88M · vs all stocks (USD)
Net Income (TTM)
-245.85MHKD-31.34M · vs all stocks (USD)
Operating Cash Flow (TTM)
-209.96MHKD-26.76M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-245.51MHKD-31.30M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
51.77MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
18.40MCNYFY2025 · Dec 31, 2025Gross Profit
33.37MCNYFY2025 · Dec 31, 2025Operating Income
-217.03MCNY-32.39M · vs all stocks (USD)
Pre-tax Income
-245.50MCNYFY2025 · Dec 31, 2025Income Tax Expense
6.00KCNYFY2025 · Dec 31, 2025Net Income
-245.51MCNYFY2025 · Dec 31, 2025EBIT
-245.38MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-207.35MCNYFY2025 · Dec 31, 2025Research & Development
124.19MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
127.08MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
124.00KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5300CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
464.82MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
464.82MSharesFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-312.43MCNYFY2025 · Dec 31, 2025Free Cash Flow
-351.49MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
652.23MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-245.50MCNYFY2025 · Dec 31, 2025Stock-based Compensation
0.00CNYFY2025 · Dec 31, 2025Other Non-cash Items
-4.82MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-16.36MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-45.74MCNYFY2025 · Dec 31, 2025Capital Expenditures
39.06MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-39.74MCNYFY2025 · Dec 31, 2025Purchase of Investments
-381.88MCNYFY2025 · Dec 31, 2025Sale of Investments
494.31MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
151.49MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
10.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-10.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
659.05MCNYFY2025 · Dec 31, 2025Shares Outstanding
517.95MSharesUpdated Sep 20, 2026Float Shares
120.74MSharesUpdated Sep 20, 2026% Held by Insiders
80.83%vs all stocks
% Held by Institutions
0.40%vs all stocks
Total Cash (MRQ)
595.44MHKD75.90M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9820HKDUpdated Sep 20, 2026Total Debt (MRQ)
255.29KHKD32.54K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0002xCurrent Ratio (MRQ)
3.69xBook Value per Share (MRQ)
2.92HKDUpdated Sep 20, 2026Total Assets
1.64BCNY244.77M · vs all stocks (USD)
Total Current Assets
832.41MCNYFY2025 · Dec 31, 2025Total Liabilities
270.09MCNYFY2025 · Dec 31, 2025Total Non-current Assets
807.93MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
48.30MCNYFY2025 · Dec 31, 2025Total Current Liabilities
221.79MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
652.23MCNYFY2025 · Dec 31, 2025Accounts Receivable
16.04MCNYFY2025 · Dec 31, 2025Inventory
86.52MCNYFY2025 · Dec 31, 2025Accounts Payable
113.57MCNYFY2025 · Dec 31, 2025Short-term Debt
647.00KCNYFY2025 · Dec 31, 2025Long-term Debt
0.00CNYFY2025 · Dec 31, 2025Common Stock (Book)
517.95MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.33BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.37BCNY204.47M · vs all stocks (USD)
52-Week Low
8.01HKDUpdated Sep 20, 202652-Week High
96.90HKDUpdated Sep 20, 202652-Week Change
-64.81%vs all stocks
50-Day MA
11.19HKDUpdated Sep 20, 2026200-Day MA
35.00HKDUpdated Sep 20, 2026Avg 10-Day Volume
3.72MSharesUpdated Sep 20, 2026Avg 30-Day Volume
2.03MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.4800HKDUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $15.42M, lower than 95% of all stocks globallySignificant
Revenue (USD): 15,422,831.374Global P5: 33,357,653.812
Market cap is $4.16B, above the global median of $1.18BNotable
Market cap (USD): 4,159,436,701.852Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Tango Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Viking Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
LivaNova PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Edgewise Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow